Portfolio Intelligence

Every signal.
Every program.
Every catalyst.

BioSignal unifies your portfolio's pipeline, competitive signals, and clinical trial activity — sourced directly from Fierce, BioPharma Dive, PubMed, ClinicalTrials.gov, and more

Sign inRequest access
Portfolio Intelligence·23 companies · 6 therapeutic areas·Signal flow · Threats · De-risking · To watch·Clinical trials · Protocol updates · New trials flagged·VC Cockpit · Next catalyst · Momentum 30d · Competitive pressure·AI brief · Thesis · Landscape · Watch-outs·Sourced live from your best sources·Portfolio Intelligence·23 companies · 6 therapeutic areas·Signal flow · Threats · De-risking · To watch·Clinical trials · Protocol updates · New trials flagged·VC Cockpit · Next catalyst · Momentum 30d · Competitive pressure·AI brief · Thesis · Landscape · Watch-outs·Sourced live from your best sources·

01 · Portfolio

Your full portfolio,
at a glance.

Companies grouped by therapeutic area. Phase, modality, and geography surface immediately. Click through to each company's full dossier — pipeline, investment thesis, and live signals.

Open portfolio
Oncology4
V
Vela Therapeutics
Q3 2026
Ph. IIIADC
A
Axon Biosciences
Ph. IImAb
N
Nara Pharma
Ph. IsiRNA
P
Pulsar Tx
PreclinicalCell therapy
AllThreatsDe-riskingTo watch
ThreatNew trial · 3d ago

Phase III competitor trial initiated — NCT0581…

De-riskingProtocol update · 8d ago

Pivotal OS data supports lead indication

To watchSignal · 12d ago

FDA Breakthrough Therapy designation granted

02 · Competitive Intelligence

Every threat.
Every de-risking.

A unified news flow across signals, clinical trials, and publications — filtered by direction. Only new or protocol-updated trials surface. Deduped by NCT, sorted by relevance.

Open news flow

03 · VC Cockpit

Read the room,
per company.

Next catalyst, 30-day momentum, competitive pressure, and last financing round — surfaced per company. The AI brief pulls thesis, landscape, and watch-outs directly from Notion.

Next catalyst

Jul 2026

Ph. III readout

Momentum (30d)

+7

signals & trials

Competitive pressure

High

3 active threats

Last round

Series C

€82M · Apr 2024